SuperworthGilead Sciences profit margin GILD
Gross, operating and net profit as a share of revenue over the last twelve months, from 2009.
- Net margin, 12 months
- −10.6%
- Operating margin, 12 months
- −8.2%
- Net margin on a year earlier
- −32.5 pts
- Peer median
- 9.8%
Over the twelve months to Jun 30, 2026, Gilead Sciences kept −10.6% of its revenue as net profit, with an operating margin of −8.2% and a gross margin of 79.6%.
Five years earlier its net margin was 19.4%.
The median for 8 large drugmakers of a similar size is 9.8%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 28.9% | 34.0% | 78.8% |
| FY2024 | 1.7% | 5.8% | 78.3% |
| FY2023 | 20.9% | 28.0% | 76.0% |
| FY2022 | 16.8% | 26.9% | 79.3% |
| FY2021 | 22.8% | 36.3% | 75.8% |
| FY2020 | 0.5% | 16.5% | 81.5% |
| FY2019 | 24.0% | 19.1% | 79.2% |
| FY2018 | 24.7% | 37.1% | 78.1% |
| FY2017 | 17.7% | 54.1% | 83.3% |
| FY2016 | 44.4% | 58.0% | 86.0% |
| FY2015 | 55.5% | 68.0% | 87.7% |
| FY2014 | 48.6% | 61.3% | 84.8% |
| FY2013 | 27.4% | 40.4% | 74.5% |
| FY2012 | 26.7% | 41.3% | 74.5% |
| FY2011 | 33.4% | 45.2% | 74.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −10.6% | −32.5 pts | −8.2% | |
| Q1 FY26 | 31.0% | +10.2 pts | 34.9% | |
| Q4 FY25 | 28.9% | +27.2 pts | 34.0% | |
| Q3 FY25 | 27.9% | +27.4 pts | 36.1% | |
| Q2 FY25 | 21.9% | +18.1 pts | 27.9% | |
| Q1 FY25 | 20.8% | +19.0 pts | 28.6% | |
| Q4 FY24 | 1.7% | −19.2 pts | 5.8% | |
| Q3 FY24 | 0.4% | −21.0 pts | 2.9% | |
| Q2 FY24 | 3.8% | −16.2 pts | 9.2% | |
| Q1 FY24 | 1.8% | −18.9 pts | 5.7% | |
| Q4 FY23 | 20.9% | +4.1 pts | 28.0% | |
| Q3 FY23 | 21.4% | +9.2 pts | 30.2% |
Against its peers
Companies in Drug Manufacturers - General nearest Gilead Sciences' size, closest first, today.
| Company | Profit margin |
|---|---|
| GILDGilead Sciences | −10.6% |
| PFEPfizer | 6.8% |
| AMGNAmgen | 23.0% |
| BMYBristol-Myers Squibb | 18.9% |
| MRKMerck | 4.8% |
| ABBVAbbVie | 9.8% |
| JNJJohnson & Johnson | n/m |
| BIIBBiogen | 8.3% |
| LLYEli Lilly and | 33.5% |
| Peer median | 9.8% |
Where Gilead Sciences ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Gilead Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.